## Michel Vallee

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4720616/publications.pdf

Version: 2024-02-01

42 papers 3,358 citations

430874 18 h-index 276875 41 g-index

42 all docs 42 docs citations

42 times ranked 4410 citing authors

#	Article	IF	CITATIONS
1	Multidisciplinary Perspectives of Current Approaches and Clinical Gaps in the Management of Hyperphosphatemia. International Journal of Nephrology and Renovascular Disease, 2021, Volume 14, 301-311.	1.8	5
2	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2018, 34, 506-525.	1.7	474
3	Single-Pill Combinations in the Treatment of Hypertension in Adults: Beyond Convenience. Canadian Journal of Diabetes, 2018, 42, 205-208.	0.8	3
4	The 2017 American College of Cardiology/American Heart Association vs Hypertension Canada High Blood Pressure Guidelines and Potential Implications. Canadian Journal of Cardiology, 2018, 34, 665-669.	1.7	11
5	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Canadian Journal of Cardiology, 2017, 33, 557-576.	1.7	269
6	Association of Neutrophil-to-Lymphocyte Ratio With Inflammation and Erythropoietin Resistance in Chronic Dialysis Patients. Canadian Journal of Kidney Health and Disease, 2017, 4, 205435811773556.	1.1	15
7	Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients. International Urology and Nephrology, 2017, 49, 325-328.	1.4	6
8	Retrospective Study Looking at Cinacalcet in the Management of Hyperparathyroidism after Kidney Transplantation. Journal of Transplantation, 2017, 2017, 1-6.	0.5	3
9	Changes in Urinary and Serum Levels of Novel Biomarkers after Administration of Gadolinium-based Contrast Agents. Biomarker Insights, 2016, 11, BMI.S39199.	2.5	6
10	Association of erythropoiesis-stimulating agents and the incidence risk of cancer diagnosis among chronic dialysis patients: a nested case–control study. Nephrology Dialysis Transplantation, 2016, 32, gfw268.	0.7	12
11	Pharmacokinetic and Dynamic of Furosemide in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2016, 36, 107-108.	2.3	3
12	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2016, 32, 569-588.	1.7	400
13	Presumed paradoxical embolus in a patient with diabetic ketoacidosis. International Journal of General Medicine, 2015, 8, 297.	1.8	O
14	The effect of lanthanum carbonate on metabolic acidosis in patients with chronic kidney disease stage IV, V and V-D. International Urology and Nephrology, 2015, 47, 1165-1171.	1.4	3
15	Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2136-2142.	4.5	124
16	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2015, 31, 549-568.	1.7	431
17	Outcomes of Infection-Related Hospitalization according to Dialysis Modality. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 817-824.	4.5	45
18	Efficacy of calcitriol compared to alfacalcidol for the treatment of secondary hyperparathyroidism in peritoneal dialysis patients. International Journal of Clinical Pharmacology and Therapeutics, 2015, 53, 895-896.	0.6	1

#	Article	IF	CITATIONS
19	Trends in infection-related hospital admissions and impact of length of time on dialysis among patients on long-term dialysis: a retrospective cohort study. CMAJ Open, 2014, 2, E109-E114.	2.4	11
20	Hemodialysis effects on phenytoin pharmacokinetics. European Journal of Clinical Pharmacology, 2014, 70, 499-500.	1.9	5
21	Comparison of oral and intravenous Alfacalcidol in chronic hemodialysis patients. BMC Nephrology, 2014, 15, 27.	1.8	8
22	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and TreatmentÂof Hypertension. Canadian Journal of Cardiology, 2014, 30, 485-501.	1.7	221
23	Conversion from twice-daily to once-daily extended-release tacrolimus in renal transplant recipients: 2-year results and review of the literature. Experimental and Clinical Transplantation, 2014, 12, 323-7.	0.5	8
24	Difficulty of patient selection in a combined heart-kidney transplant: a case report. Experimental and Clinical Transplantation, 2014, 12, 273-6.	0.5	2
25	Magnitude of discordance between registry data and death certificate when evaluating leading causes of death in dialysis patients. BMC Medical Research Methodology, 2013, 13, 51.	3.1	9
26	The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2013, 29, 528-542.	1.7	163
27	The role of sevelamer carbonate in increasing serum bicarbonate in hyperphosphatemic predialysis patients who have metabolic acidosis. International Journal of Clinical Pharmacology and Therapeutics, 2013, 51, 989-990.	0.6	3
28	Ten-year experience with fungal peritonitis in peritoneal dialysis patients: antifungal susceptibility patterns in a North-American center. International Journal of Infectious Diseases, 2012, 16, e41-e43.	3.3	31
29	The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2012, 28, 270-287.	1.7	173
30	Association of Dialysis Modality with Risk for Infection-Related Hospitalization. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1598-1605.	4.5	42
31	The 2011 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2011, 27, 415-433.e2.	1.7	127
32	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I – blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2010, 26, 241-248.	1.7	170
33	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy. Canadian Journal of Cardiology, 2010, 26, 249-258.	1.7	191
34	Comparison of the prevalence of calcidiol insufficiency in predialysis and osteoporotic populations. International Urology and Nephrology, 2009, 41, 983-988.	1.4	8
35	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part $1$ $\hat{a}$ $\in$ " blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2009, 25, 279-286.	1.7	60
36	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 $\hat{a} \in \text{``therapy. Canadian Journal of Cardiology, 2009, 25, 287-298.}$	1.7	111

#	Article	IF	CITATION
37	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy. Canadian Journal of Cardiology, 2008, 24, 465-475.	1.7	78
38	High mortality after pelvis and lower limb fractures in ESRD. CKJ: Clinical Kidney Journal, 2008, 1, 466-466.	2.9	4
39	Isolation and characterization of the monkey UDP-glucuronosyltransferase cDNA clone monUGT1A01 active on bilirubin and estrogens. Journal of Steroid Biochemistry and Molecular Biology, 2001, 77, 239-249.	2.5	14
40	Characterization of UDP-glucuronosyltransferases active on steroid hormones. Journal of Steroid Biochemistry and Molecular Biology, 1999, 69, 413-423.	2.5	101
41	Regulation of 21-Hydroxylase activity by steroids. Endocrine Research, 1995, 21, 329-341.	1.2	5
42	Regulation of guinea pig adrenal P450c21 messenger RNA, protein and activity by RU486. Journal of Steroid Biochemistry and Molecular Biology, 1995, 54, 31-38.	2.5	2